Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Depreciation & Amortization (CF) (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $390000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 3.72% to $390000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 16.01% decrease, with the full-year FY2025 number at $1.4 million, down 13.12% from a year prior.
  • Depreciation & Amortization (CF) was $390000.0 for Q4 2025 at Fulcrum Therapeutics, up from $300000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $700000.0 in Q2 2021 to a low of $300000.0 in Q2 2025.
  • A 5-year average of $507400.0 and a median of $522000.0 in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): rose 26.58% in 2021, then dropped 29.08% in 2024.
  • Fulcrum Therapeutics' Depreciation & Amortization (CF) stood at $615000.0 in 2021, then decreased by 6.18% to $577000.0 in 2022, then decreased by 11.96% to $508000.0 in 2023, then dropped by 25.98% to $376000.0 in 2024, then rose by 3.72% to $390000.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Depreciation & Amortization (CF) are $390000.0 (Q4 2025), $300000.0 (Q3 2025), and $300000.0 (Q2 2025).